Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

18. Juni 2026 aktualisiert von: Hangzhou Highlightll Pharmaceutical Co., Ltd

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

This study is a randomized, double-blind, placebo-controlled, multicenter Phase Ib/II clinical study designed to evaluate the efficacy, safety, and PK characteristics of HL-300 ointment with different concentration regimens for mild-to-moderate AD.

Studienübersicht

Detaillierte Beschreibung

In the study, it is planned to enroll approximately 148-156 trial participants, divided into two cohorts. Cohort 1: a randomized, double-blind, placebo-parallel controlled study design, planning to enroll 140 trial participants, randomized in a 1:1:1:1 ratio to the study group or placebo group, with baseline disease severity (mild [vIGA-AD = 2] and moderate [vIGA-AD = 3]) set as stratification factors to ensure balanced participant status across groups. Cohort 2: an open-label, intensive sampling design, planning to enroll 8 trial participants for each dosage strength, enrolled separately, with continuous dosing for 8 days.

The study includes a screening period, a treatment period, and a follow-up period. The quality management system for this trial aims to prospectively integrate quality by design into all aspects of the trial to ensure the rights and interests, safety, and well-being of trial participants, and to guarantee the reliability of the generated data and the scientific validity of the trial results. This system strictly adheres to the principles of ICH E6(R3) and ICH E8(R1), employing a risk-based and proportionate approach.

During the trial design phase, the investigators have systematically identified the critical to quality (CtQ) factors for ensuring the quality of this trial. Given the known safety profile of JAK inhibitors (e.g., infections, hematologic abnormalities, hepatic and renal function effects, thrombosis, etc.), the CtQ factors for this trial will specifically focus on:

  • Trial participant safety: Identification, recording, assessment, and timely reporting of Adverse Events (AEs) and Serious Adverse Events (SAEs).
  • Key efficacy data: Accuracy and integrity of data collection related to the primary and secondary endpoints of the trial (e.g., vIGA-AD, EASI, BSA, WI-NRS, DLQI, SCORAD, etc.).
  • Critical processes: Strict adherence to inclusion/exclusion criteria during participant screening [e.g., exclusion of severe infections (including herpes zoster, tuberculosis, and other opportunistic infections) and active infections, hematologic toxicity (anemia, neutropenia), elevated transaminases, and high-risk thrombosis population], protocol-mandated laboratory tests (e.g., blood routine, blood biochemistry, urinalysis, coagulation function, etc.), completeness of randomization and blinding, concomitant medication management (e.g., contraindications for topical medications for AD or AD-related skin infections, systemic treatments for AD, systemic immunosuppressants or immunomodulators, other JAK inhibitors, etc.), rules for suspension/termination of dosing.

Studientyp

Interventionell

Einschreibung (Geschätzt)

156

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Zhejiang
      • Hangzhou, Zhejiang, China
        • Rekrutierung
        • Hangzhou First People's Hospital
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  1. Age ≥18 years and ≤75 years at the time of ICF signing, with no gender restriction
  2. Meeting the Hanifin & Rajka diagnostic criteria for atopic dermatitis (AD) at screening, with a history of AD ≥ 6 months before screening, and the AD condition judged by the investigator to be stable within 4 weeks prior to ICF signing,.
  3. vIGA-AD score of 2-3 at screening and baseline visits;
  4. EASI score within the range of 5-21 at screening and baseline;
  5. "Body Surface Area (BSA) affected by AD skin lesions meeting one of the following requirements at screening and baseline visits, with skin lesions suitable for topical treatment:

    • Cohort 1: BSA of 5% to 20%;
    • Cohort 2: BSA of 15% to 25%. "
  6. Women of childbearing potential and men willing to use at least one highly effective method of contraception or practice abstinence from the time of informed consent signing until 3 months after the last dose of the investigational product
  7. Those who voluntarily participate in the study and sign the informed consent form

Exclusion Criteria:

  1. "Trial participants with any of the following medical histories or abnormal conditions at screening: (1) Skin lesions or abnormalities that may affect the assessment of the investigational product application site; (2) Clinically relevant skin diseases that are contraindicated for the study or affect the assessment of the application site, including but not limited to: psoriasis, acne, skin cancer; (3) Other autoimmune diseases besides AD, such as inflammatory bowel disease, rheumatoid arthritis, where the investigator believes the disease would unfavorably impact the assessment of this study; (4) Current or history of lymphoproliferative disorders, or signs or symptoms suggestive of possible lymphoproliferative disorders, including lymphadenopathy or splenomegaly; (5) Any malignancy, or any history of malignancy within 5 years prior to screening (except for completely resected cervical carcinoma in situ or non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, or papillary thyroid carcinoma); (6) History of herpes virus infection within the past 6 months, or recurrent herpes zoster (≥2 episodes), disseminated herpes zoster, disseminated herpes simplex, or current inability to rule out herpes zoster or herpes simplex infection; (7) Systemic infection requiring hospitalization within 12 weeks prior to screening to baseline, or active bacterial, viral, fungal, parasitic, or other infections requiring anti-infective treatment within 4 weeks prior to screening to baseline; (8) Local active infection within 1 week prior to screening to baseline, such as active infected AD, or any superficial skin infection requiring oral or intravenous antibiotic, antifungal, or antiviral medication; (9) History of thrombotic events, including deep vein thrombosis and pulmonary embolism, or high-risk factors for thromboembolism (e.g., immobilization or prolonged bed rest), which is judged by the investigator's comprehensive clinical assessment to be unsuitable for participation in this study; (10) History of significant cardiovascular, neurological, respiratory, hematological, digestive, urinary, immune, or psychiatric diseases that the investigator believes may confound study results or affect drug absorption, distribution, metabolism, and excretion, or place the trial participant at undue risk; (11) History of drug abuse or substance abuse."
  2. "Trial participants who have received any of the following treatments: (1) Use of topical skin products for AD or AD-related skin infections at the study application site within 2 weeks prior to baseline, including but not limited to: topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), topical phosphodiesterase 4 (PDE-4) inhibitor ointments, topical antimicrobials, etc.; (2) Use of topical skin products containing chemically active ingredients (including but not limited to vitamin E cream, functional products containing niacinamide/urea/ceramide, excluding emollients without any chemically active ingredients) at the study application site within 1 week prior to baseline; (3) Use of systemic therapeutic drugs for AD within 4 weeks or 5 half-lives (whichever is longer) prior to baseline, including but not limited to systemic anti-infectives, PDE-4 inhibitors, and systemic traditional Chinese medicine or herbal medicines for AD; (4) Use of systemic or topical JAK inhibitors (such as ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib, delgocitinib, upadacitinib, abrocitinib, etc.) within 12 weeks prior to baseline; (5) Use of sedating antihistamines within 2 weeks prior to baseline (Stable use of non-sedating antihistamines is permitted [dose stable for 2 weeks or 5 half-lives (whichever is longer) before the first study medication]); (6) Use of systemic immunosuppressants or immunomodulators (such as oral or injectable corticosteroids, methotrexate, cyclosporine, mycophenolate mofetil, and azathioprine) within 4 weeks or 5 half-lives (whichever is longer) prior to baseline; (7) Use of biologics (such as dupilumab) within 12 weeks or 5 half-lives (whichever is longer) prior to baseline; (8) Use of strong CYP450 inhibitors or inducers within 2 weeks prior to baseline, including but not limited to: nelfinavir, ritonavir, clarithromycin, itraconazole, nevirapine, and barbiturates; (9) Vaccination with live/attenuated live vaccines within 4 weeks prior to baseline, or planning to receive vaccination during the study period; (10) Sunbathing or phototherapy (including ultraviolet therapy, photochemotherapy, etc.) with AD therapeutic effects within 4 weeks prior to baseline;"
  3. "Trial participants with any of the following laboratory and instrumental examination results:

(1) Any significant clinical and laboratory abnormalities that the investigator believes may affect trial participant safety, including but not limited to:

  1. White blood cell count (WBC) < 3×109/L, absolute neutrophil count (ANC) < 1.5×109/L, absolute lymphocyte count (ALC) < 0.8×109/L, platelet count (PLT) < 100×109/L, hemoglobin (Hb) < 100 g/L;
  2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2× ULN, or total bilirubin (TBIL) ≥ 1.5× ULN;
  3. Blood creatinine > 1.5× ULN; (2) Confirmed or suspected active tuberculosis, incompletely cured tuberculosis, or active Mycobacterium tuberculosis infection (except for trial participants with documented treatment proving adequate therapy, who may enter this study based on the medical judgment of the investigator and/or infectious disease specialist) judged by the investigator and/or infectious disease specialist (combining medical history, symptoms, signs, laboratory tests, tuberculosis screening tests, and imaging findings); (3) QT interval corrected by Fridericia formula (QTcF) ≥500 ms in 12-ECG results at screening; (4) Hepatitis B surface antigen (HBsAg) positive; HBsAg negative but hepatitis B core antibody (HBcAb) positive and HBV-DNA above detection limit, or human immunodeficiency virus antibody (HIV) positive, or anti-hepatitis C virus (HCV) antibody positive and HCV-RNA positive, or Treponema pallidum antibody positive (excluding trial participants with negative non-specific syphilis antibody results and judged by the investigator to have a past history of syphilis infection that has been cured);" 4.Known or suspected allergy to the investigational product or excipients in the investigational product; 5.Female trial participants who are suspected or known to be pregnant, breastfeeding, or planning pregnancy during the trial period; 6.History of major surgery within 4 weeks prior to baseline or planned surgery during the study; 7.Significant blood loss, received blood transfusion, or donated blood (≥400 mL) within 3 months prior to baseline; 8.Participation in other clinical trials within 3 months prior to baseline; 9.Weekly alcohol consumption greater than 14 units within 3 months prior to screening (1 unit of alcohol ≈ 360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine); 10.Other conditions judged by the investigator to be unsuitable for participation in the study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Gruppe D
BID, day 7.
Experimental: Group A
Group A:0.25%
Group A receives the investigational product at a concentration of 0.25%, BID,4 weeks.
Group B receives the investigational product at a concentration of 0.5%, BID,4 weeks.
Group A receives the investigational product at a concentration of 1.0%, BID,4 weeks.
Experimental: Group B
Group B:0.5%
Group A receives the investigational product at a concentration of 0.25%, BID,4 weeks.
Group B receives the investigational product at a concentration of 0.5%, BID,4 weeks.
Group A receives the investigational product at a concentration of 1.0%, BID,4 weeks.
Experimental: Group C
Group C:1.0%
Group A receives the investigational product at a concentration of 0.25%, BID,4 weeks.
Group B receives the investigational product at a concentration of 0.5%, BID,4 weeks.
Group A receives the investigational product at a concentration of 1.0%, BID,4 weeks.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Eczema Area and Severity Index (EASI)
Zeitfenster: 4 weeks

Percentage change from baseline in Eczema Area and Severity Index (EASI) score at Week 4 (W4).

The EASI score ranges from 0 to 72, with higher scores indicating more severe AD.

4 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Eczema Area and Severity Index(EASI)
Zeitfenster: at Weeks 1, 2, 3, and 6 after treatment.
Change from baseline in EASI score at Weeks 1, 2, 3, 4, and 6 after treatment. The EASI score ranges from 0 to 72, with higher scores indicating more severe AD.
at Weeks 1, 2, 3, and 6 after treatment.
EASI50(≥50% improvement from baseline in EASI score)
Zeitfenster: at Weeks 1, 2, 3, 4, and 6 after treatment

Proportion of trial participants with ≥50% improvement from baseline in EASI score (EASI50) at Weeks 1, 2, 3, 4, and 6 after treatment.

The EASI score ranges from 0 to 72, with higher scores indicating more severe AD.

at Weeks 1, 2, 3, 4, and 6 after treatment
EASI75(≥75% improvement from baseline in EASI score)
Zeitfenster: at Weeks 1, 2, 3, 4, and 6 after treatment

Proportion of trial participants with ≥75% improvement from baseline in EASI score (EASI75) at Weeks 1, 2, 3, 4, and 6 after treatment.

The EASI score ranges from 0 to 72, with higher scores indicating more severe AD.

at Weeks 1, 2, 3, 4, and 6 after treatment
EASI90(≥90% improvement from baseline in EASI score)
Zeitfenster: at Weeks 1, 2, 3, 4, and 6 after treatment.

Proportion of trial participants with ≥90% improvement from baseline in EASI score (EASI90) at Weeks 1, 2, 3, 4, and 6 after treatment.

The EASI score ranges from 0 to 72, with higher scores indicating more severe AD.

at Weeks 1, 2, 3, 4, and 6 after treatment.
Validated Investigator Global Assessment for Atopic Dermatitis(vIGA-AD)
Zeitfenster: at Weeks 1, 2, 3, 4, and 6 after treatment.

Proportion of trial participants achieving vIGA-AD score of 0 (clear) or 1 (almost clear) and ≥2-point improvement from baseline at Weeks 1, 2, 3, 4, and 6 after treatment.

The vIGA-AD scale divides disease severity into 5 grades (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), each corresponding to specific skin lesion morphological characteristics. A higher grade indicates greater severity.

at Weeks 1, 2, 3, 4, and 6 after treatment.
Validated Investigator Global Assessment for Atopic Dermatitis(vIGA-AD)
Zeitfenster: at Weeks 1, 2, 3, 4, and 6 after treatment.

Proportion of trial participants achieving vIGA-AD score of 0 or 1 at Weeks 1, 2, 3, 4, and 6 after treatment.

The vIGA-AD scale divides disease severity into 5 grades (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), each corresponding to specific skin lesion morphological characteristics. A higher grade indicates greater severity.

at Weeks 1, 2, 3, 4, and 6 after treatment.
Numeric Rating Scale (NRS)
Zeitfenster: at Weeks 1, 2, 3, 4, and 6 after treatment.

Change from baseline in weekly average itch Numeric Rating Scale (NRS) at Weeks 1, 2, 3, 4, and 6 after treatment.

This scale assesses the most severe itch intensity subjectively felt by the trial participant due to AD in the past 24 h. The scale rates itch intensity on 10 levels (0 means no itch, 10 means the worst itch imaginable), with integer scores.The higher the score, the greater the disease severity.

at Weeks 1, 2, 3, 4, and 6 after treatment.
Numeric Rating Scale (NRS)
Zeitfenster: at Weeks 1, 2, 3, 4, and 6 after treatment

Percentage of trial participants with ≥4-point improvement from baseline in weekly average itch NRS at Weeks 1, 2, 3, 4, and 6 after treatment.

This scale assesses the most severe itch intensity subjectively felt by the trial participant due to AD in the past 24 h. The scale rates itch intensity on 10 levels (0 means no itch, 10 means the worst itch imaginable), with integer scores.The higher the score, the greater the disease severity.

at Weeks 1, 2, 3, 4, and 6 after treatment
Scoring Atopic Dermatitis(SCORAD)
Zeitfenster: at Weeks 1, 2, 3, 4, and 6 after treatment.

]Change from baseline and percentage change from baseline in Scoring Atopic Dermatitis (SCORAD) at Weeks 1, 2, 3, 4, and 6 after treatment.

The SCORAD score ranging from 0 to 103 points. Based on the score, the condition is classified as mild (0-24 points), moderate (25-50 points), and severe (>50 points).

at Weeks 1, 2, 3, 4, and 6 after treatment.
Body Surface Area (BSA)
Zeitfenster: at Weeks 1, 2, 3, 4, and 6 after treatment.

Change from baseline and percentage change from baseline in Body Surface Area (BSA) affected by AD at Weeks 1, 2, 3, 4, and 6 after treatment.

The BSA ranges from 0% to 100%. The larger the range, the more severe the affected area.

at Weeks 1, 2, 3, 4, and 6 after treatment.
Dermatology Life Quality Index (DLQI)
Zeitfenster: at Weeks 1, 2, 3, 4, and 6 after treatment.

Change from baseline in Dermatology Life Quality Index (DLQI) score at Weeks 1, 2, 3, 4, and 6 after treatment.

DLQI contains 10 questions, with a total score ranging from 0 to 30.The higher the score, the greater the impact on quality of life.

at Weeks 1, 2, 3, 4, and 6 after treatment.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Wu Liming NA, Doctor of Medicine, First People's Hospital of Hangzhou

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

26. Mai 2026

Primärer Abschluss (Geschätzt)

30. Juni 2027

Studienabschluss (Geschätzt)

31. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

1. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

1. Juni 2026

Zuerst gepostet (Tatsächlich)

5. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

23. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

18. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren